Keywords: Multiple sclerosis, ECTRIMS highlights, Novartis, Gilenya, GW Pharma, Almirall, Sativex, Sanofi, Genzyme, Aubagio

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio

Article | 14 October 2012

Print This

New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in